ProQR Therapeutics NV (MEX:PRQRN) Cyclically Adjusted FCF per Share: MXN-20.52 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PRQRN ProQR Therapeutics NV MEX:PRQRN
50 GF Score
Price MXN36.00
GF Value MXN39.89
! 2 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Cyclically Adjusted FCF per Share?

ProQR Therapeutics NV MEX:PRQRN 50 Cyclically Adjusted FCF per Share is MXN-20.52 as of Jun. 2026. GuruFocus rates MEX:PRQRN with a GF Score™ of 50/100 and a GF Value™ of MXN39.89. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ProQR Therapeutics NV's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN-2.296. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN-20.52 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-01), ProQR Therapeutics NV's current stock price is MXN36.00. ProQR Therapeutics NV's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN-20.52. ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF of today is .


ProQR Therapeutics NV  (MEX:PRQRN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ProQR Therapeutics NV Cyclically Adjusted FCF per Share Related Terms


ProQR Therapeutics NV Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Cyclically Adjusted FCF per Share Chart

ProQR Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -17.45 -16.30 -20.14

ProQR Therapeutics NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.65 -19.61 -20.14 -24.44 -20.52

MEX:PRQRN vs NWBO, IMRX, VNDA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF falls into.


MEX:PRQRN
50GF Score
ProQR Therapeutics NV MEX:PRQRN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProQR Therapeutics NV Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ProQR Therapeutics NV's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-2.296/137.7700*137.7700
=-2.296

Current CPI (Jun. 2026) = 137.7700.

ProQR Therapeutics NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -10.424 100.570 -14.280
201612 -6.865 100.710 -9.391
201703 -7.574 101.440 -10.287
201706 -8.375 101.370 -11.382
201709 -6.524 102.030 -8.809
201712 -7.058 101.970 -9.536
201803 -6.817 102.470 -9.165
201806 -4.031 103.100 -5.387
201809 -2.850 103.950 -3.777
201812 -5.244 103.970 -6.949
201903 -7.095 105.370 -9.277
201906 -6.116 105.840 -7.961
201909 -4.919 106.700 -6.351
201912 -5.387 106.800 -6.949
202003 -7.894 106.850 -10.178
202006 -5.628 107.510 -7.212
202009 -5.228 107.880 -6.677
202012 -5.725 107.850 -7.313
202103 -5.648 108.870 -7.147
202106 -3.637 109.670 -4.569
202109 -2.917 110.790 -3.627
202112 1.157 114.010 1.398
202203 -6.365 119.460 -7.341
202206 -4.492 119.050 -5.198
202209 -4.355 126.890 -4.728
202212 -5.079 124.940 -5.601
202303 10.638 124.720 11.751
202306 -2.442 125.830 -2.674
202309 -1.801 127.160 -1.951
202312 -1.350 126.450 -1.471
202403 -3.508 128.580 -3.759
202406 -1.575 129.910 -1.670
202409 -1.590 131.610 -1.664
202412 -2.082 131.630 -2.179
202503 -3.365 133.330 -3.477
202506 -2.371 133.960 -2.438
202509 -2.535 135.920 -2.570
202512 -2.778 135.270 -2.829
202603 -2.238 136.910 -2.252
202606 -2.296 137.770 -2.296

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN-20.52 mean?
ProQR Therapeutics NV (MEX:PRQRN) has a Cyclically Adjusted FCF per Share of MXN-20.52 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ProQR Therapeutics NV and its competitors.
Is ProQR Therapeutics NV's Cyclically Adjusted FCF per Share too high?
ProQR Therapeutics NV's current Cyclically Adjusted FCF per Share is MXN-20.52. Overall, ProQR Therapeutics NV has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Cyclically Adjusted FCF per Share compare to NWBO and IMRX?
ProQR Therapeutics NV's Cyclically Adjusted FCF per Share of MXN-20.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Cyclically Adjusted FCF per Share is MXN-20.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current Cyclically Adjusted FCF per Share of MXN-20.52. The stock's GF Value™ is MXN39.89, compared to a current price of MXN36.00 — trading 9.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN-20.52. ProQR Therapeutics NV's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current Cyclically Adjusted FCF per Share is MXN-20.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of MXN36.00 is trading 9.8% below its estimated GF Value™ of MXN39.89.

Key valuation signals for MEX:PRQRN:

  • Cyclically Adjusted FCF per Share: MXN-20.52
  • GF Value™: MXN39.89 vs. price of MXN36.00 (9.8% below fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ProQR Therapeutics NV Business Description

Other Exchanges PRQR:USA0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
50GF Score

Get the complete analysis for MEX:PRQRN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN36.00
Price
MXN39.89
GF Value